Rabah Iratni* and Mohammed Akli Ayoub Pages 1 - 12 ( 12 )
The concept of drug repurposing and Sildenafil or blue pill are tightly linked over the years. Indeed, in addition to its initial clinical application as an anti-hypertensive drug in the pulmonary system, Sildenafil is also known for its beneficial effects in erectile dysfunction. Moreover, evidence have been accumulated to support its value in anti-cancer therapy either alone or in a combination with other clinically efficient chemotherapy drugs. In this review, we focused on the old and recent in vitro and in vivo studies demonstrating the cellular and molecular rationale for the application of Sildenafil in combination therapy in many various types of cancer. We emphasized on the different molecular targets as well as the different signaling pathways involved in cancer cells. The pro-apoptotic effect of Sildenafil through nitric oxide (NO)/ phosphodiesterase type 5 (PDE5)-dependent manner seems to be one of the most common mechanisms. However, the activation of autophagy as well as the modulation of the anti-tumor immunity constitute the other pathways triggered by Sildenafil. Overall, the studies converged to reveal the complexity of the anti-cancer potential of Sildenafil. Thus, through our review we aimed to present an updated and simplified picture of such repurposing of Sildenafil in the field of oncology.
Sildenafil, Drug repurposing, PDE-5 inhibitor, cancer, Combination therapy.
Department of Biology, College of Science, United Arab Emirates University, P.O. Box: 15551, Al Ain, Department of Biology, College of Science, United Arab Emirates University, P.O. Box: 15551, Al Ain